E -Pharmacy | Engelle Clean, Anti -Heart failure medicine from hypoglycemic medicine

At present, more than 60 million patients with heart failure worldwide have become a global public health problem. As the prevalence of heart failure increases, people's demand for new treatment and new solutions is becoming increasingly urgent.

Heart failure, referred to as heart failure, is an obstacle disease of the heart function. Generally, it is manifested as a reduction in myocardial contraction or obstacles that cause reduced heart emissions and the reduction of blood supply to the body tissue. Heart failure can be divided into three different types, mainly due to the reduced heart failure (ejaculation score of ejection), heart failure of the critical range (40%-49%) of the critical range (40%-49%) The heart failure retained in the score (ejaculation score> 50%). With the progress of drug research, Engelbund can not only treat type 2 diabetes, but also to treat heart failure with reduced ejection scores.

Why is Engelle Jingpai used for anti -heart failure

Due to the close correlation between cardiovascular, kidney, and endocrine systems, a system functional disorder may cause other dysfunction. Engelbon can reduce blood sugar levels by inhibiting renal tubular glucose to reducing blood sugar, and at the same time, there is also the function of diuretic, moderate weight loss, increased blood cell ratio, and blood pressure.

The 2015 EMPA-Reg OutCome test proves that Engelbon can greatly reduce the risk of death of patients with type 2 diabetes with cardiovascular disease. Emperor-PRESERVED random, parallel, double-blind, placebo comparison in 2021. A total of 5,988 patients have shown that whether there is diabetes or not, Engel's net can effectively reduce the cardiovascular vessels of patients with ejaculation scores. The risk of death or heart failure. In 2021, the American Cardiac Society updated the expert consensus management of patients with reduced ejection scores. On the basis of the "New Golden Triangle" treatment, SGLT2I formed a "four -play". In June of this year, the National Drug Administration approved the Patin patient patients who were used in the treatment of ejection scores, which further affirmed the status of Energy Cyrine's anti -heart failure status.

Precautions for using Engel

Because Engel column can reduce the blood glucose of patients with type 2 diabetes, when used for type 2 diabetes with heart failure, pay attention to blood glucose monitoring to avoid hypoglycemic hypoglycemia. Engen column also has diuretic effects. When combined with other diuretics, pay attention to blood capacity. In the case of combined dehydration diseases, avoid using Engelle. Engel column can cause genital mold infections, and personal hygiene should be paid during the medication. Permonicon may also have acidosis, including shortage of breathing, nausea, vomiting, abdominal pain, blurred consciousness, anorexia, thirst and drowsiness. In addition, Engelbald Patients with type 1 diabetes.

Conclusion

At present, Engelbon has been approved in the United States and Europe for the treatment of all symptoms of adults, regardless of whether the ejection score is reduced or the ejection score reserves. In our country, Engelbede has also been approved to treat the symptoms of chronic heart failure for the treatment of ejection scores. It is expected that the development of related domestic research after approval can bring more clinical data that suits Chinese people. Approval can benefit more patients.

references:

1.braunwald: SGLT2 Inhibitors have influent CV careless of diabetes status. Healio. August 26, 2020.

2.Stefan D. Anker, Javed Butler, Gerasimos Filippatos, et al. Empagliflozin in Heart Failure with a Preserved ENGL J Med. August 27, 2021.. 2021.

3.Eileen O'Meara, Michael McDonald, Michael Chan, et al. CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis. Can J Cardiol. 2020; 36 (2): 159-169.

Part of the picture comes from the network

Author / Deputy Director of Pharmacy Department of Zhuzhou Second Hospital Liu Longzhen

Edit / Ye Guiqiu, Affairs Center

Review / Professor Zou Yuhua, a professor at Guangdong Pharmaceutical University

- END -